Story perspectives

Zevra's Miplyffa Approved: Groundbreaking Niemann-Pick Treatment Launches

5/23/2025

27 4

Summary

Story summary

Zevra Therapeutics has made history with the FDA's approval of Miplyffa® (arimoclomol), the first-ever treatment for Niemann-Pick disease type C. This milestone was followed by a lucrative $150 million sale of a Rare Pediatric Disease Priority Review Voucher, significantly enhancing Zevra's financial standing. The launch of Miplyffa has surpassed expectations, with 122 patients already enrolled in its expanded access program, showcasing a robust demand for this groundbreaking therapy.

1 of 1

Story summary

Zevra Therapeutics has made history with the FDA's approval of Miplyffa® (arimoclomol), the first-ever treatment for Niemann-Pick disease type C. This milestone was followed by a lucrative $150 million sale of a Rare Pediatric Disease Priority Review Voucher, significantly enhancing Zevra's financial standing. The launch of Miplyffa has surpassed expectations, with 122 patients already enrolled in its expanded access program, showcasing a robust demand for this groundbreaking therapy.